Invention Grant
US08735405B2 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
有权
6,6-双环取代杂双环蛋白激酶抑制剂
- Patent Title: 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
- Patent Title (中): 6,6-双环取代杂双环蛋白激酶抑制剂
-
Application No.: US13446629Application Date: 2012-04-13
-
Publication No.: US08735405B2Publication Date: 2014-05-27
- Inventor: Lee D. Arnold , Cara Cesario , Heather Coate , Andrew P. Crew , Hanqing Dong , Kenneth Foreman , Ayako Honda , Radoslaw Laufer , An-Hu Li , Kristen Michelle Mulvihill , Mark J. Mulvihill , Anthony I. Nigro , Bijoy Panicker , Arno G. Steinig , Yingchuan Sun , Quinghua Weng , Douglas S. Werner , Michael J. Wyle , Tao Zhang
- Applicant: Lee D. Arnold , Cara Cesario , Heather Coate , Andrew P. Crew , Hanqing Dong , Kenneth Foreman , Ayako Honda , Radoslaw Laufer , An-Hu Li , Kristen Michelle Mulvihill , Mark J. Mulvihill , Anthony I. Nigro , Bijoy Panicker , Arno G. Steinig , Yingchuan Sun , Quinghua Weng , Douglas S. Werner , Michael J. Wyle , Tao Zhang
- Applicant Address: US NY Farmingdale
- Assignee: OSI Pharmaceuticals, LLC
- Current Assignee: OSI Pharmaceuticals, LLC
- Current Assignee Address: US NY Farmingdale
- Agency: Astellas US LLC
- Agent Guyan Liang
- Main IPC: A01N43/90
- IPC: A01N43/90 ; A61K31/519 ; C07D487/00
Abstract:
Compounds of the formula and pharmaceutically acceptable salts thereof, wherein X1, X2, X3, X4, X5, X6, X7, R1, and Q1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.
Public/Granted literature
- US20120196847A1 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors Public/Granted day:2012-08-02
Information query
IPC分类:
